Ivermectina Giuliani

Ivermectin, the active ingredient in Ivermectina Giuliani, is an antiparasitic presented as an oral tablet for oral use. It is employed to treat a range of parasitic infections in both adults and children, targeting diseases such as onchocerciasis, strongyloidiasis, scabies, pediculosis and other intestinal helminth infections.

GNH USA supplies Ivermectina Giuliani as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectina Giuliani is an antiparasitic drug that acts on a variety of helminth and ectoparasite infections. - Onchocerciasis (river blindness): reduces microfilarial load and helps prevent disease progression. - Strongyloidiasis: eliminates intestinal larvae and prevents dissemination. - Scabies: eradicates Sarcoptes scabiei mites, relieving skin lesions. - Pediculosis (lice infestation): kills head and body lice, stopping infestation spread. - Other intestinal helminth infections: clears a broad spectrum of nematodes, improving gastrointestinal health.

Ivermectina Giuliani may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness: mild, transient sensation of light‑headedness. - Nausea: occasional upset stomach. - Diarrhea: loose stools that resolve spontaneously. - Abdominal pain: mild cramping. - Pruritus: itching at the site of infestation or drug administration. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe skin reactions: including rash, Stevens‑Johnson syndrome. - Hepatic injury: elevated liver enzymes or jaundice. - Neurologic toxicity: seizures, confusion, or ataxia. - Hypotension: sudden drop in blood pressure. - Anaphylaxis: rare systemic allergic response. - Visual disturbances: blurred vision or optic neuritis.

Before prescribing Ivermectina Giuliani, clinicians should consider several safety aspects. - Assess hypersensitivity: avoid in patients with known allergy to ivermectin or excipients. - Evaluate liver function: use caution in moderate to severe hepatic impairment. - Review concomitant CNS drugs: monitor for enhanced neurotoxicity when combined with other central nervous system depressants. - Pregnancy and lactation: safety data are limited; weigh potential benefits against risks. - Pediatric use: dosing must be determined by a qualified prescriber based on weight. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Ivermectina Giuliani can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivermectin plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil): can raise systemic exposure. - Co‑administration with other antiparasitics: risk of additive neurotoxicity.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Diethylcarbamazine: may increase risk of neurologic side effects. - Antifungal azoles (moderate inhibitors): observe for increased ivermectin exposure.